Results 1 to 10 of about 4,561,781 (108)
Some of the next articles are maybe not open access.

CERIF Tutorial: Autumn 2022 Strategic Membership Meeting Nijmegen

open access: yes, 2022
63 slidesCERIF Tutorial delivered by the euroCRIS Board member and Lead for the CERIF and CRIS Architectures Task Group Jan Dvořák at the Autumn 2022 Strategic Membership Meeting held Nov 30-Dec 2, 2022 in Nijmegen, the ...
Dvořák, Jan
core  

2022 Texas Bays and Estuaries Meeting [PDF]

open access: yes, 2022
Program for the 2022 Texas Bays and Estuaries Meeting held in Port Aransas, Texas, September 21-22, 2022.Marine ...
University of Texas Marine Science Institute
core   +1 more source

A meta-analysis of longitudinal studies to evaluate predictive role of arterial stiffness in cardiovascular and all cause mortality

open access: yes, 2016
- 19. The 64th Annual Scientific Meeting of the Cardiac Society of Australia and New Zealand held in conjunction with the 40th Annual Scientific Meeting of the International Society for Heart ResearchAbstract not availableK. Khokhar, M.
Munawar, D.   +7 more
core   +1 more source

Diagnostic utility of Cardiac Magnetic Resonance Imaging (CMR) in Myocardial Infarction with Non Obstructive Coronary Arteries (MINOCA) patients

open access: yes, 2016
- 90. The 64th Annual Scientific Meeting of the Cardiac Society of Australia and New Zealand held in conjunction with the 40th Annual Scientific Meeting of the International Society for Heart ResearchS. Pasupathy, R. Tavella, R. Potamianos, M. Arstall, D.
Beltrame, J.   +7 more
core   +1 more source

TeaP 2022 - Abstracts of the 64th Conference of Experimental Psychologists

open access: yes, 2022
Contains abstracts of all conference contributions and an author index of the 64th Conference of Experimental ...

core   +1 more source

Safety, Efficacy, and Pharmacokinetics of Unecritinib (TQ‐B3101) in Pediatric Patients With Relapsed/Refractory Anaplastic Lymphoma Kinase‐Positive Anaplastic Large‐Cell Lymphoma: A Phase I Study

open access: yesMedComm, Volume 7, Issue 11, November 2026.
This Phase I study evaluated unecritinib (TQ‐B3101) in pediatric patients with relapsed/refractory ALK+ anaplastic large‐cell lymphoma. Unecritinib showed a manageable safety profile without dose‐limiting toxicities and achieved remarkable efficacy, with a 100% overall response rate.
Suying Lu   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy